Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
U.S. Patent and Trademark Office extends protection of Clearmind’s proprietary MEAI and expands its potential market Tel Aviv, Israel /...
U.S. Patent and Trademark Office extends protection of Clearmind’s proprietary MEAI and expands its potential market Tel Aviv, Israel /...
NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
MAINZ, GERMANY, December 21, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable...
Brain Activate - ENERGY Gel Brain Activate - ENERGY Gel is a rapidly absorbed focus and cognitive enhancer that is...
Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows...
AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time...
ST. LOUIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment...
– Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities – – Plan to Dose Additional Participants...
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid...
Phase 3, registrational studies remain on track for first half of 2023 topline data readoutSCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE...
LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T...
INDIANAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development,...
POTOMAC, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today...
Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroupBUFFALO, N.Y., Dec....
FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
-- FemCath™ is the first FDA-cleared intrauterine catheter that allows for selective evaluation of a fallopian tube with contrast -- --...
BEIJING, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of...
Hamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Provides Year-End 2022 Business Update Strategic BentrioTM partnering or divestiture...
Dr. Uribe is the fourth national KOL to join the Aclarion team this year. Development of this program supports Aclarion’s...
MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across...